{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:15:52Z","timestamp":1791090952063,"version":"4.1.0"},"reference-count":30,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2009,7,27]],"date-time":"2009-07-27T00:00:00Z","timestamp":1248652800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurourology and Urodynamics"],"published-print":{"date-parts":[[2010,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>There is evidence that antimuscarinic drugs have depressant influence not only on bladder muscle activity, but also on bladder sensations. The aim of this study was to evaluate the effect of a single dose tolterodine extended release (ER) 4 and 8\u2009mg on bladder sensations during filling cystometry.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>After approval of the local ethics committee, 30 healthy female subjects (23.7\u2009\u00b1\u20092.3 years) were included and randomly assigned to three groups: (A) placebo, (B) tolterodine ER 4\u2009mg, and (C) tolterodine ER 8\u2009mg in a double blind manner. Measurements were performed at baseline and 4\u2009hr postmedication in each group, consisting of: (1) Filling cystometry with 25\u2009ml\/min at which subjects had to indicate first sensation of filling (FSF), first desire to void (FDV), and strong desire to void (SDV). (2) Uroflowmetry and ultrasound control for residual urine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the placebo group, filling volumes at FDV and SDV decreased significantly posttreatment. This effect could not be observed for the tolterodine 8\u2009mg group and only at SDV in the 4\u2009mg group. No significant difference between groups was found regarding uroflowmetry parameters and postvoid residual volume.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>No increase of filling volumes in healthy subjects could be observed with tolterodine. However, the results suggest that tolterodine is able to alleviate irritation caused by repeated catheterization and cystometry. There was no significant influence of tolterodine ER 4 or 8\u2009mg on voiding function. Neurourol. Urodynam. 29:464\u2013469, 2010. \u00a9 2009 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/nau.20743","type":"journal-article","created":{"date-parts":[[2009,7,28]],"date-time":"2009-07-28T10:29:59Z","timestamp":1248776999000},"page":"464-469","source":"Crossref","is-referenced-by-count":5,"title":["Proof of principle: The effect of antimuscarinics on bladder filling sensations in healthy subjects\u2014A placebo controlled double blind investigation using 4 and 8\u2009mg tolterodine extended release"],"prefix":"10.1002","volume":"29","author":[{"given":"Ulrich","family":"Mehnert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Reitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumaya Abo","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Schurch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,7,27]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)02243-4"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20472"},{"key":"e_1_2_1_4_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0302-2838(02)00540-7","article-title":"Antimuscarinics and the overactive detrusor\u2014Which is the main mechanism of action?","volume":"43","author":"Andersson KE","year":"2003","journal-title":"Eur Urol"},{"key":"e_1_2_1_5_2","doi-asserted-by":"crossref","unstructured":"NabiG CodyJD EllisG et al.2006.Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane database of systematic reviews (Online)(4):CD003781.","DOI":"10.1002\/14651858.CD003781.pub2"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000155798.78911.57"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706780"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20208"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.03.006"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2004.11.021"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000176793.50410.9e"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140030-00006"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02201987"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.1998.00501.x"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.1930140606"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-2838(02)00221-X"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.1993.sp019604"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.10019"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20039"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001920200018"},{"key":"e_1_2_1_21_2","first-page":"35","article-title":"Long term reproducibility of urodynamic investigations in healthy fertile females","volume":"114","author":"Sorensen S","year":"1988","journal-title":"Scand J Urol Nephrol"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20444"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.03.032"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.02.009"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2007.06903.x"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20095"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(01)00914-1"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(03)00622-7"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706604"},{"key":"e_1_2_1_30_2","first-page":"287","article-title":"Pharmacokinetics and pharmacodynamics of tolterodine in man: A new drug for the treatment of urinary bladder overactivity","volume":"35","author":"Brynne N","year":"1997","journal-title":"Int J Clin Pharmacol Ther"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140020-00005"}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fnau.20743","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.20743","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T21:56:43Z","timestamp":1700517403000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.20743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,27]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["10.1002\/nau.20743"],"URL":"https:\/\/doi.org\/10.1002\/nau.20743","archive":["Portico"],"relation":{},"ISSN":["0733-2467","1520-6777"],"issn-type":[{"value":"0733-2467","type":"print"},{"value":"1520-6777","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,27]]}}}